Forte Biosciences (FBRX) Other Accumulated Expenses (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Other Accumulated Expenses data on file, last reported at $82000.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 25.45% year-over-year to $82000.0 in Q1 2026; TTM through Mar 2026 was $82000.0, a 25.45% decrease from a year earlier, with the FY2025 full-year figure at $8000.0, down 93.94% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $82000.0, up from $8000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for FBRX reached as high as $141000.0 in Q1 2022 and fell as low as $3000.0 in Q4 2023.
• Historically, Other Accumulated Expenses has averaged $54750.0 across 5 years, with a median of $43500.0 in 2022.
• Across the five-year window, Other Accumulated Expenses soared 4300.0% in 2024 and plunged 93.94% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $8000.0 in 2022, then slumped by 62.5% to $3000.0 in 2023, then surged by 4300.0% to $132000.0 in 2024, then plunged by 93.94% to $8000.0 in 2025, then surged by 925.0% to $82000.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $82000.0 in Q1 2026, $8000.0 in Q4 2025, and $30000.0 in Q3 2025.